Related references
Note: Only part of the references are listed.Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
A. K. Gandhi et al.
CURRENT CANCER DRUG TARGETS (2010)
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
S. K. Kumar et al.
LEUKEMIA (2010)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani et al.
BLOOD (2009)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul Richardson et al.
BLOOD (2009)
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
Edward A. Stadtmauer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide: a novel anticancer drug with multiple modalities
Christine Galustian et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24
Olaf Christensen et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma
Ross D. Brown et al.
LEUKEMIA & LYMPHOMA (2009)
Treatment of Relapsed/Refractory Multiple Myeloma
Efstathios Kastritis et al.
SEMINARS IN HEMATOLOGY (2009)
Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma
Oliver C. Goodyear et al.
BLOOD (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
Jianfei Qian et al.
BLOOD (2007)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications
YT Tai et al.
CANCER RESEARCH (2005)
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
F van Rhee et al.
BLOOD (2005)
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma
C Choi et al.
BLOOD (2005)
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
E Carbone et al.
BLOOD (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Anti-myeloma activity of natural killer lymphocytes
C Frohn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Share Paper
